Westfield Capital Management
LENZ

Westfield Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Westfield Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,159
Closed -$261K – 282
2025
Q1 		$261K Buy
+10,159
New +$250K ﹤0.01% 242

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Westfield Capital Management's LENZ Position: Q2 2025 in Review

Westfield Capital Management sold out of LENZ Therapeutics (LENZ) in Q2 2025, closing a stake of 10,159 shares — an estimated $261K sold.

Westfield Capital Management first reported a position in LENZ in Q1 2025 and held it in 1 quarter. The position peaked at $261K in Q1 2025. 113 funds tracked by Wall St. Rank hold LENZ as of Q2 2025.

  • Westfield Capital Management reported no remaining LENZ Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Westfield Capital Management sold 10,159 LENZ Therapeutics shares in Q2 2025, an estimated $261K.
  • Westfield Capital Management first reported a position in LENZ Therapeutics in Q1 2025 and held it in 1 quarter.
  • Westfield Capital Management's LENZ Therapeutics position peaked at $261K in Q1 2025.
  • 113 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2025.

Based on Westfield Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.